Abstract CT237: A randomized phase 2 non-inferiority trial of (Z)-endoxifen + goserelin and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE)
Matthew P. Goetz(Mayo Clinic), Steven C. Quay(Aptevo Therapeutics (United states)), Pooja Advani(Jacksonville College), Sarah A. Buhrow(Mayo Clinic), Amy C. Degnim(Mayo Clinic in Arizona), Daniel Flora(St. Elizabeth Healthcare), Felipe Batalini(Beth Israel Deaconess Medical Center), Joel M. Reid(Children's Hospital of Philadelphia), Jason M. Jones, Judy C. Boughey(Mayo Clinic in Arizona), John R. Hawse(Mayo Clinic in Arizona), Katie N. Hunt(Mayo Clinic), Nusayba A. Bagegni(Washington University in St. Louis), Roberto A. Leon‐Ferre(Mayo Clinic), Lida A. Mina(Mayo Clinic in Arizona), Mara A. Piltin(Mayo Clinic), Clàudia López(Aptevo Therapeutics (United states)), Vera J. Suman(Mayo Clinic in Arizona), James N. Ingle(Mayo Clinic), Karthik V. Giridhar(WinnMed), Lonnissa Nguyen(Aptevo Therapeutics (United states)), Sandra S. Hammer, Matthew J. Schellenberg(Mayo Clinic)
Cited by 0
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
|Clinical Cancer Research|2013|744